insights_auto
Why is ARCT down 13.96%?
Dive Deeperchevron_right
ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$9.49
arrow_downward
-13.96%(-1.54) 1D
$9.73
arrow_upward
+2.53% (+0.24)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
$11.00
High
$11.05
Low
$9.42
Mkt. cap
269.73M
Avg. vol.
753.56K
Volume
1.00
52-wk high
$17.96
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
Open
$11.00
High
$11.05
Low
$9.42
Mkt. cap
269.73M
Avg. vol.
753.56K
Volume
1.00
52-wk high
$17.96
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
News stories
From web sources and news partners
MarketWatch
·
17 minutes ago
This signal from the corporate bond market has historically preceded big drawdowns for the S&P 500
BigGo Finance
·
43 minutes ago
NYSE Taps Broadridge to Run Onchain Voting for Its Tokenized Stock Venue
Investing.com
·
28 minutes ago
Nasdaq sank -5.3%, but these AI strategies surged up to +9.3% in October
The Motley Fool
·
48 minutes ago
The Company Behind the New York Stock Exchange Is Now Building on Hyperliquid. Here's What It Means for Investors.
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc